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Abstract Children diagnosed with diffuse intrinsic pontine
glioma (DIPG) face a dismal prognosis, with severe neuro-
logic deterioration and inevitable death at a median of
9 months from diagnosis. Steroids are widely prescribed as
supportive or palliative treatment although they are known
to cause severe side effects that may reduce the quality of
life. This study aims to review the current knowledge on, and
use of, steroids in DIPG patients. A global questionnaire-
study among health care professionals was performed to
ascertain information on the current (multi-)institutional and
(multi-)national use of steroids, the availability of clinical
guidelines, and the need for improvements in prescribing
steroids to DIPG patients. In addition, an extensive literature
search was performed to review studies investigating ster-
oids in pediatric brain tumor patients. From 150 responding
health care professionals, only 7 % had clinical guidelines.
The use of steroids was heterogeneous and over 85 % of
respondents reported serious side effects. Fourteen articles,
with low level of evidence, described the use of steroids in
pediatric brain tumor patients. Clinical trials investigating
optimal dose or regimen were lacking. This study is a first
inventory of the availability of evidence-based information
and clinical guidelines, and the current attitude towards the
use of steroids in DIPG patients. To date, the risk–benefit
ratio of steroids in this disease is yet to be determined. We
emphasize the need for clinical trials resulting in guidelines
on steroids, and possibly alternative drugs, to optimize the
quality of care and quality of life of DIPG patients.
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Introduction
Diffuse intrinsic pontine glioma (DIPG) is a childhood brain
tumor that grows diffusely in between the critical structures
of the brainstem. Patients have a two-year survival rate of
less than 10 % [1]. Given the poor prognosis and lack of
effective treatment options, maintenance of a good quality of
life for as long as possible should be a major goal in the
management approach of DIPG patients. Steroids are widely
prescribed as supportive or palliative treatment. They are,
however, well known to cause numerous side effects, which
in turn may comprise the patient’s quality of life. To date,
little research into the risk–benefit ratio and use of steroids in
DIPG patients has been performed.
Symptoms in DIPG patients are a result of either direct
tumor invasion and destruction of the critical brainstem
structures, or tumor- or edema induced compression.
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Elevated tissue pressure by tumor and edema results in the
classical neurological triad of cranial nerve deficits,
extremity weakness and ataxia at time of diagnosis [2]. As
the tumor grows, the increase in clinical symptoms inex-
orably leads to a further decrease in the quality of life, and
tumor-induced compression and destruction of critical
structures for autonomic functioning inside the brainstem
eventually heralds death. Edema formation or bleeding
within the tumor may accelerate this deterioration. Steroids
are used to temporarily relieve symptoms caused by peri-
tumoral edema and are thought to prolong life at end-stage
disease.
Although steroids have proven to be very effective in
reducing peritumoral edema, they are known to cause
substantial side effects, especially with continuous use.
Side effects include sleep disorders, mood and behavioral
changes, insatiable appetite, weight gain and Cushing’s
syndrome, often accompanied by disfiguring striae and a
‘moon face’, completely changing the appearance of the
child [3]. These side effects substantially compromise
quality of life. It is therefore of the utmost importance to
weigh the risks and benefits of steroid treatment.
In this study we aim to survey how health care profes-
sionals who manage DIPG patients use steroids in daily
practice (e.g., which drugs, dosages, duration and sched-
ules). In addition, we provide an evidence-based overview
of the current literature on the use of steroids in DIPG and
other pediatric brain tumor patients. The ultimate purpose
of this study is to provide a needs-assessment, to facilitate
the development of a steroid treatment guideline to opti-
mize care and quality of life of DIPG patients.
Materials and methods
International online survey
To ascertain information on the current multi-institutional
and multi-national use of steroids in DIPG patients, the
availability of clinical guidelines, and to learn possible
points for improvement in prescribing steroids to DIPG
patients, an international survey, using an online ques-
tionnaire, was developed and distributed among health care
professionals specialized in DIPG.
The survey assessed the institutional use of steroids; e.g.
prescribed drugs (type of steroid), dose and dosing sched-
ule, route of administration, duration of steroid therapy,
time of initiation during disease course, and tapering reg-
imens. Different types of steroid doses were converted to
dexamethasone equivalents in mg per m2 per day by
multiplying with 0.1875 for methylprednisolone, 0.15 for
prednisone/prednisolone and 1.25 for betamethasone.
Doses given in mg/kg/day were converted by
multiplication with 30 [4]. An average prescribed dose was
thus calculated for each respondent. For tapering regimens,
the duration over which the dose was reduced, and to what
extent, was analyzed. No differentiation was made between
the use of steroids at the time of diagnosis and/or at the
time of palliation. Instead, the respondents were asked a
general question on when steroids are usually prescribed
during the disease course (e.g. at time of diagnosis, during
radiotherapy, at relapse and/or at the terminal phase of the
disease). The observed effects and side effects of steroid
treatment were ascertained. Availability of local clinical
guidelines was asked. Items of this questionnaire may be
found in the Supplementary Material.
The survey was distributed world-wide to experts
treating children with brain tumors, via the electronic
mailing lists of the International Society of Paediatric
Oncology Europe (SIOPE) Brain Tumour Group, the
International Society of Paediatric Neuro-oncology
(ISPNO) and the International Brain Tumor Alliance
(IBTA). Two weeks after the initial distribution, a reminder
was sent. The survey was also promoted in the online
newsletter from the IBTA.
Statistical analysis
The data from the survey were analyzed by descriptive
statistical methods using IBM SPSS Statistics for Win-
dows, Version 20.0 (Armonk, NY: IBM Corp. Released
2011). Nominal categorical variables were descriptively
analyzed regarding to the observed frequencies. Numerical
variables were evaluated using central tendency and dis-
persion measures.
Review of the literature
To identify all possible information on the use of steroids
in children with brain tumors, a review of the current lit-
erature was performed to obtain evidence-based informa-
tion, especially on clinically studied drugs and dosages,
and the duration and/or schedules that have been tested
thus far. In advance of the search, it was known that lit-
erature on the use of steroids in DIPG patients is scarce. It
was therefore our explicit purpose to broaden the search to
all pediatric brain tumors, in an aim to find information that
is translatable to DIPG patients.
The complete databases of Medline/PubMed, Embase
and The Cochrane Library were searched for relevant
articles. The search strategy combined controlled and free
text words for the target population (e.g. children), the
tumor type (e.g. brain tumors), the underlying pathophys-
iology (e.g. edema) and all types of steroidal drugs.
Inclusion criteria were: case reports, clinical studies and
literature reviews investigating the use of steroids for
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pediatric brain tumor patients. The complete search strat-
egy may be found in the supplementary material.
Results
Online international questionnaire-study
One hundred and fifty health care professionals who
manage DIPG patients from 31 countries responded to the
online survey (Fig. 1). It was not possible to determine the
response rate from the electronic mailing lists of the
SIOPE, ISPNO and the IBTA, as (1) it was unclear how
many professionals were included, (2) these lists also
include professionals not directly involved in the treatment
of DIPG patients, and (3) professionals were also asked to
forward this invitation to the survey to colleagues within
their institution and/or national groups. In total, profes-
sionals from 20 European and 11 non-European completed
the survey. Most respondents were pediatric oncologists
(121, 81 %). Others included radiotherapists, pediatric
neurologists or pediatric neurosurgeons (supplementary
material). The health care professionals answering the
questionnaire treated a median of two DIPG patients per
year (range 1–25 patients). There were 11 professionals,
working in larger volume centers located in the Italy
(n = 3), the United Kingdom (n = 1), the United States of
America (n = 6) and Argentina (n = 1) who indicated
treating eight or more DIPG patients each year.
The vast majority, 93 % of respondents, responded that
no specific guideline for the prescription of steroids was
used in their institution. Guidelines were available in all
but one of the larger volume centers. Sixty-seven percent
of those that used a guideline were willing to share this
with the community.
Steroid therapy was in most cases initiated by a pediatric
oncologist (82 %) or radiotherapist (18 %). Neurosur-
geons, general pediatricians, family doctors or parents are
less likely to lead on the initiation (supplementary mate-
rial). Steroids are prescribed during the entire disease
course (e.g. at time of diagnosis, during radiotherapy, at
relapse and at the terminal phase of the disease; Fig. 2),
without a clear pattern, but prescription is mainly driven by
clinical symptoms
The types of steroids used are dexamethasone, methyl-
prednisolone, betamethasone, prednisolone and prednisone.
The vast majority of respondents (91 %) prescribe dex-
amethasone (supplementary material). The most common
Fig. 1 Geographical distribution of respondents to the international online survey
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route of administration is oral, which is rarely combined or
interspersed with intravenous administration (supplemen-
tary material). Heterogeneous dosing was observed, both in
dose as in duration. Converted doses varied from 1.5 to
52.5 mg/m2/day with a median of 8.5 mg/m2/day (Fig. 3).
Steroid prescription was slightly less heterogeneous in
European countries and in larger volume centers, ranging
from 2.25 to 22.5 mg/m2/day (median 8 mg/m2/day) and
2.25–30 mg/m2/day (median 8.5 mg/m2/day), respectively.
The duration varied from 3 to 75 days with a median of
15 days (Fig. 4). Stopping or tapering regimens also var-
ied; most respondents (75 %) always taper, whereas 9 % of
respondents do not taper steroid therapy but stop instantly
and 16 % taper if the steroids were prescribed over a
‘longer period of time’ (i.e. prescription ranging from[5
to[14 days). The tapering regimen duration varied from 1
to 35 days and the dose reduction per step varied from 10
to 50 % per day, or 0.1–4.0 mg/m2/day. For tapering and
duration there was no difference observed between larger
or smaller volume centers.
Commonly observed steroid side effects, as described by
more than 85 % of respondents were: mood changes,
obesity, food craving, personality changes, depression,
Cushing’s syndrome, insomnia, muscle atrophy, skin
thinning, hypertension and edema (Fig. 5). Long-term
steroid-induced side effects of steroid administration were
less often described; immunosuppression (e.g. increased
infections), bone demineralization, diabetes mellitus, ele-
vated liver enzymes, adrenal insufficiency and fatty liver
degeneration. Occurrence of allergic reactions along with
steroid administration was described by 23 % of the
respondents.
Sixty-eight percent of respondents believe that steroids
are of great help in management of symptoms in DIPG
patients, although it is acknowledged that there is a tight
balance between benefits and side effects of steroids in
these patients. Forty-six percent of respondents hold the
opinion that the observed side effects do not outweigh the
established efficacy and 77 % of respondents state that
steroid alternatives are urgently needed. To overcome or
reduce side effects, 16 % of respondents use alternatives to
steroids. Reported alternatives included bevacizumab,
boswelic acids, osmotic diuretics, mannitol, acetazolamide,
Fig. 2 The pattern of steroid
prescription during the disease
course
Fig. 3 Distribution of steroid dosage. Starting dose converted to
dexamethasone equivalents
Fig. 4 Distribution of steroid treatment duration
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celecoxib, and high dose bicarbonate (supplementary
material). More than 70 % of the respondents agree with
the statement that steroid regimens are to be investigated in
DIPG patients and that an international DIPG steroid
guideline should be developed for these patients.
Literature review
The literature search resulted in 844 records. Fourteen
papers were selected for full text analysis [3, 5–17].
Excluded papers investigated the use of steroids in animals,
adults, and children with steroid use for other indications
(i.e. asthma, nephrotic syndrome, leukemia, trauma,
meningitis, etc.).
Table 1 shows the complete list of studies investigating
or describing the use of steroids in pediatric brain tumor
patients, and their level of evidence. Full text analysis,
revealed that most papers describe the use of dexametha-
sone, with doses ranging from 0.15 mg/kg/day (4.5 mg/
m2/day) [11] to 2.0 mg/kg/day (60 mg/m2/day) [15]. Only
four studies describe the effects of steroid use [5, 10, 12,
14]. Table 2 shows the side effects of steroid use that were
reported in the papers.
Discussion
Our extensive worldwide survey with 150 respondents
from all over the world provides a good overview of the
current use of steroids in DIPG patients. This international
survey uncovers an absence of clinical guidelines, a
strikingly heterogeneous use of steroids in DIPG patients,
and a significant amount of reported side effects. A meager
11 (7 %) of the surveyed health care professionals
indicated to have a clinical guideline available. These
guidelines were mainly used in larger volume centers.
Steroids are prescribed throughout the entire DIPG disease
course and almost all known side effects from steroid use
occur in over 50 % of patients. Oral dexamethasone is by
far the most common prescription, but the dosages, dura-
tion and tapering regiments showed such a wide variety
that the current data are insufficient to develop clinical
recommendations. In some cases it was even questionable
whether the responses reflect the reality, with respondents
indicating to dose as low as 1.5 mg/m2/day up to as high as
52.5 mg/m2/day. A limitation of the survey, however, is the
fact that it did not separately address steroid prescription at
the time of diagnosis from prescription at time of disease
progression. Furthermore, respondents were not asked
whether steroids were prescribed in the context of a clinical
trial. This may have influenced the results of the obtained
dose-range and should be taken into account in future
studies. Finally, health care professionals indicate that both
optimization of steroid therapy and exploration of alter-
native options to steroid therapy are urgently needed in an
aim to provide better supportive and palliative care for
patients suffering from a DIPG.
For children with DIPG, treatment is essentially pallia-
tive and quality of life is of paramount importance [18].
Although steroids are widely prescribed, we show that
there is a striking lack of literature and evidence available
on this important topic. Only 14 studies report on the
effects and/or side effects of steroid use in pediatric brain
tumor patients. Only four studies focus on DIPG patients
specifically [6, 7, 13, 15]. Most articles have low level of
evidence, do not specifically study the use of steroids and
more importantly, clinical trials determining the optimal
drugs, dosage and schedules are lacking. The dosages that
were found in the literature show a great diversity when
Fig. 5 Reported steroid side
effects. Dotted line reported
by[85 % of respondents
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converted to dexamethasone equivalents: from a 4 mg
single dose up to a cumulative 24-h dose of 66 mg/m2 in
young patients undergoing brainstem surgery/biopsy [8,
10]. The observed diversity was partly related to the indi-
cation for steroid therapy. Merely four articles report on the
positive effects of steroids, which in most cases is a
reduction of clinical symptoms [5, 10, 12, 14] and in one
case changes observed by MR-imaging [14]. One article
reports a possible negative effect of steroids: a decrease of
the blood–brain barrier (BBB) permeability to (water sol-
uble) cytotoxic agents aimed at treating the tumor [3]. The
possibly more important negative effect of immunosup-
pression, namely a reduction of anti-tumor immunogenic-
ity, is not mentioned in any of the articles from the
literature search [19]. Twelve articles report on steroid side
effects, but only two studies performed active prospective
registration [11, 15]. To conclude, in literature there cur-
rently is no high-level evidence on the (side) effects and
optimum steroidal drugs, dosages, duration and schedules
for children suffering DIPG.
The results of our study show that clinical guidelines on
the use of steroids are urgently needed. To substantiate
these guidelines, further research is warranted, investigat-
ing both steroid schedules, for instance by means of ran-
domizing between short courses of high dosages and
prolonged use of lower dosages, as well as studies into
more patient friendly alternatives to steroids, such as
bevacizumab, boswelic acids, and possibly corticotropin-
releasing factor (hCRF) analogue corticorelin acetate [18,
20–22], or palliative re-irradiation [23]. Prospective (ran-
domized) clinical trials specifically developed for DIPG
patients are a prerequisite, since edema-related symptoms
in these patients occur more frequently and rapidly than in
patients suffering from other types of brain tumors. Also,
the balance of the risk–benefit ratio may be different in
DIPG patients: as there is no curative treatment yet, it
should be judiciously considered whether one should
extend life by the use of steroids, whilst incurring side
effects that decrease the quality of life. Outcome measures
such as performance score and quality of life should
Table 1 Result of the literature search
Ref.
nr.
Year Author Study type Patient type Disease What was reported Level of evidence
[24]
[5] 1986 Schmid Retrospective
analysis
38 adults/23 children Fossa posterior tumors Effect of steroids 2B
[6] 1988 Freeman Single arm Phase 1 34 children (aged
3–21)
Brain stem tumors Side effects of
steroids
4
[7] 1991 Freeman Single arm Phase 1 57 children (aged
3–21)
Brain stem tumors Side effects of
steroids
4
[8] 1995 Toftegaard Case report 15 year-old girl Brain tumor Side effect of
steroids
5
[3] 1997 Glaser Descriptive 62 children CNS tumors Side effects of
steroids
2C
[9] 1998 Wolff Retrospective
analysis
20 children Brain tumors Side effects of
steroids
2B
[10] 2000 Mursch Retrospective
analysis
55 children Brain stem tumors Effect of steroids 2B
[11] 2002 Edelbauer Double arm study 60 children (aged
1–18)
Brain tumors Side effects of
steroids
1B
[12] 2008 Mallur Case report 5 year-old boy JPA Effect of steroids 5
[13] 2010 Broniscer Single arm Phase 1 21 children (aged
2–20)
DIPG Side effects of
steroids
4
[14] 2010 Meyzer Case report 10 year-old boy Oligodendroglioma Effect of steroids 5
[15] 2011 Beltran Single arm 15 children (aged
2–13)
DIPG Side effects of
steroids
1B
[16] 2012 Wheeler Case report 12 year-old boy Supratentorial GBM Side effects of
steroids
5





Complete list of studies investigating or describing the use of steroids in pediatric brain tumor patients, and their level of evidence
Ref. nr. reference number, JPA Juvenile pilocytic astrocytoma, GBM Glioblastoma multiforme
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therefore be carefully recorded, in parallel to recording of
BMI and observed side effects. In the design of a
prospective clinical trial, there will be a number of chal-
lenges, such as the rarity of the disease resulting in prob-
lems to power the trial or to address the many variations of
use obtained from our worldwide survey, but possibly also
breaking well-established individual-experience based
practices that oncologists may not be willing to stop, and
finally human subjects protection concerns related to this
vulnerable group of patients. We therefore would recom-
mend commencing the prospective registration of current
practices in the prescription of steroids in DIPG patients.
Such aims can be facilitated by the recent establishment of
the SIOPE DIPG registry (http://www.dipgregistry.eu) by
the SIOPE DIPG network, and the International DIPG
registry (http://www.dipgregistry.org). Prospective regis-
tration should include all items from the survey, and should
be designed for longitudinal registration (e.g. during all
phases of the disease course). Prophylaxis during pro-
longed steroid prescription, such as for Pneumocystis jir-
oveci pneumonia (PJP), should also be assessed. In order to
allow the collection of uniform data, standardized case
report forms will be developed and included in the reg-
istries shortly.
To conclude, this study has provided insight in the
current wide variety of steroid use in DIPG. We believe
that prospective registration of current practices is a pre-
requisite step in advance of the development of a
Table 2 Reported side effects of steroid use in pediatric brain tumor patients
Reference number: [6] [7] [8] [3] [9] [11] [14] [16] [17] [18]
Personality-/mental-/behavioral-/mood changes * * *
Gastrointestinal (peptic) ulcer, hemorrhage and perforation/gastritis * *
Increased/insatiable appetite *
Moon face/obesity/weight gain * * * *
Altered body habitus *
Iatrogenic cushing syndrome *
Abnormal glucose tolerance/elevated blood glucose * * *
Diabetic ketoacidosis *
Osteoporosis * * *
Aseptic bone necrosis *
Hypertension * * * *
Posterior reversible encephalopathy syndrome (PRES) *
Glaucoma *
Addisonian crisis risk up to 1 year after cessation *
(Proximal) myopathy * *
Cataract *
Reduced permeability of BBB to chemotherapeutic agents
Skin atrophy/abdominal striae (striae sistensae)/interference with wound healing *
Glucocorticoid-induced and vasopressin-resistant polyuria *
Hepatotoxicity *
*Glutamate oxalacetate transaminase (GOT) *
*Glutamate pyrovate transaminase (GPT) *
Altered immune response/immunosuppression/opportunistic infections * * * * *
*Inhibition of the transcription of IL-4/IFN-c/TNF-a/IL-3/IL-5 *
*Enhancement of in vitro IL-4 production in PBMCs *
*Shift towards the Th2 humoral immune response *
*IgE antibody production with danger of anaphylactic reactions *





Significant decrease in Quality of Life *
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multinational clinical trial and a future guideline. Deter-
mining the risk–benefit ratio of steroid use will be chal-
lenging, but is needed to optimize supportive care and
quality of life for patients suffering from DIPG.
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